A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma
Status:
Completed
Trial end date:
2017-10-06
Target enrollment:
Participant gender:
Summary
This is a phase I study incorporating bavituximab into the care of patients with rectal
adenocarcinoma simultaneously treated with capecitabine and radiation therapy. There is no
reference therapy as we are trying to identify the MTD of bavituximab in this combination.